Cycle Pharmaceuticals Ltd.
Privately held: no public share price
Assets
(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Approved | Nrf2 pathway (fumaric acid ester)Small molecule | Multiple Sclerosis | |
| Approved | S1P receptorSmall molecule | Multiple Sclerosis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.